Multicenter Cohort Study of Infliximab Pharmacokinet
Pediatric Acute Severe Ulcerative Colitis

Clinical Gastroenterology and Hepatology

21, 1338-1347

DOI: 10.1016/j.cgh.2022.08.016

Citation Report

#	Article	IF	Citations
1	In-Hospital Management of Inflammatory Bowel Disease. Current Opinion in Gastroenterology, 2023, 39, 274.	3.2	13
2	The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America, 2023, 52, 549-563.	3.6	6
3	Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis. Journal of Clinical Medicine, 2023, 12, 3378.	3.8	22
4	Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports, 2023, 25, 323-332.	4.9	14
5	Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-Centre, Prospective, Paediatric Cohort Study. Journal of Crohn's and Colitis, 2024, 18, 233-245.	8.8	17
6	The Combination of Predictive Factors of Pharmacokinetic Origin Associates With Enhanced Disease Control During Treatment of Pediatric Crohn's Disease With Infliximab. Pharmaceutics, 2023, 15, 2408.	7.5	10
7	Drug Clearance in Patients With Inflammatory Bowel Disease Treated With Biologics. Journal of Clinical Medicine, 2023, 12, 7132.	3.8	49
8	Ustekinumab for Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis: A Promising Approach Towards Endoscopic Healing. Intestinal Research, 2024, 22, 351-356.	4.0	9
9	Acute Severe Ulcerative Colitis Management: Unanswered Questions and Latest Insights. The Lancet Gastroenterology and Hepatology, 2024, 9, 251-262.	29.4	79
10	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement From the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2024, 46, 291.	2.2	26
11	Infliximab in Paediatric Inflammatory Bowel Disease: External Evaluation of Population Pharmacokinetic Models. British Journal of Clinical Pharmacology, 2024, 90, 2200-2214.	3.0	5
12	Precision Medicine: Externally Validated Explainable AI Support Tool for Predicting Sustainability of Infliximab and Vedolizumab in Ulcerative Colitis. Digestive and Liver Disease, 2024, 0, 2069-2076.	4.4	8
13	Predicting Complications in Paediatric Ulcerative Colitis: A Longitudinal Multicentre Cohort Study. Alimentary Pharmacology and Therapeutics, 2024, 60, 1421-1434.	7.7	7
14	Monoclonal Antibodies Against Pediatric Ulcerative Colitis: A Review of Clinical Progress. Expert Opinion on Biological Therapy, 2024, 24, 1133-1144.	3.5	2
15	Model-Informed Precision Dosing in Inflammatory Bowel Diseases. Trends in Pharmacological Sciences, 2025, 46, 9-19.	19.8	6
16	Intensified Infliximab Induction Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis. The Lancet Gastroenterology and Hepatology, 2025, 10, 18-19.	29.4	1
17	Intensified Infliximab Induction Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis. The Lancet Gastroenterology and Hepatology, 2025, 10, 17-18.	29.4	0
18	Eleven Grand Challenges for Inflammatory Bowel Disease Genetics and Genomics. Inflammatory Bowel Diseases, 2025, 31, 272-284.	5.5	8

#	Article	IF	Citations
19	Advancements in the Management of Pediatric Inflammatory Bowel Disease. Expert Review of Gastroenterology and Hepatology, 2024, 18, 815-827.	3.5	7
20	Biologics in the Management of Pediatric Inflammatory Bowel Disease: When and What to Choose. World Journal of Clinical Pediatrics, 2025, 14, 100938.	3.3	6
21	Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Paediatric Patients With Inflammatory Bowel Disease. Journal of Clinical Medicine, 2025, 14, 845.	3.8	6
22	Integrating Early Response Biomarkers in Pharmacokinetic Models: A Novel Method to Individualize the Initial Infliximab Dose in Patients With Crohn's Disease. Clinical and Translational Science, 2025, 18, e70086.	4.1	5
23	Intensified Upadacitinib Dosing for Adolescent Patients With Acute Severe Ulcerative Colitis. Children, 2025, 12, 401.	3.0	7
24	Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Updated Evidence-Based Consensus Guideline From the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 816-851.	3.3	30
25	Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC. Gastroenterology, 2026, 170, 118-131.	12.5	26
26	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 1100-1117.	3.3	22
27	Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2025, 14, 7956.	3.8	3
28	Anti-Tumor Necrosis Factor-α Monotherapy Versus Combo Therapy With Immunosuppressant in Pediatric Inflammatory Bowel Disease: A Real-Life Study. Journal of Pediatric Gastroenterology and Nutrition, 2026, 82, 454-464.	3.3	0
29	Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted With Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab Dosing. Digestive Diseases and Sciences, 2026, 71, 1-8.	3.0	1
30	Managing Acute Severe Ulcerative Colitis in 2025 and Beyond. Current Gastroenterology Reports, 2026, 28, 3.	4.9	9
31	Neutrophils in Inflammatory Bowel Disease: Disease-Promoting Versus Protective Functions. Frontiers in Immunology, 2026, 16, 1750743.	6.9	10
32	Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature. Gastro Hep Advances, 2026, 5, 100953.	2.4	0
33	Acteurs Déclenchants Microbiens dans la Colite Aigue Grave de Rectocolite Hémorragique et Leur Influence sur la Réponse au Traitement Médical : Une Approche Multidimensionnelle. , 2023, .		0
34	Early Infliximab Levels and Clearance Predict Outcomes in Acute Severe Ulcerative Colitis. Translational Gastroenterology and Hepatology, 2026, 11, 82.	3.0	0
35	Review: Optimizing Rescue Therapy in Acute Severe Ulcerative Colitis Using Infliximab Pharmacokinetics—A Practical Guide for Clinicians. Journal of Crohn's and Colitis, 2026, .	8.8	0